Eledon Pharmaceuticals

NEWS

Pictured: Illustration of gloved hands using tools

Biotech Bay

Eledon’s Antibody Aids First Gene-Edited, Pig-to-Human Kidney Transplant

Tegoprubart, Eledon Pharmaceuticals’ experimental anti-CD40L antibody, was part of the immunosuppressive treatment regimen used following the first-ever transplant of a kidney from a genetically modified pig to a human.

March 22, 2024

4 min read

Tyler Patchen

IN THE PRESS

Biotech Beach

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

March 21, 2024

6 min read

Biotech Beach

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 14, 2024

February 13, 2024

1 min read

Business

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

January 4, 2024

6 min read

Biotech Beach

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 04, 2023

December 4, 2023

2 min read

Biotech Beach

Eledon Pharmaceuticals to Present at Noble Capital Markets’ Emerging Growth Equity Conference

November 29, 2023

1 min read

Business

Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

November 9, 2023

9 min read

Biotech Beach

Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference 2023

November 8, 2023

1 min read

Drug Development

Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

November 2, 2023

7 min read

Business

Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

October 23, 2023

3 min read

Biotech Beach

Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

October 13, 2023

1 min read

JOBS